Boston Scientific Corp.'s stock spiked more than 2 percent on news that the company has reached a $275 million settlement with the Internal Revenue Service over transfer pricing issues associated with the company's $27 billion acquisition of Guidant Corp. in 2006. When finalized, the settlement will remove a potential headwind, and demonstrate Boston Scientific's continued recovery from the disastrous takeover of the cardiology implant maker.